The Institute of Medicine of Sunflower Pharmaceutical Group (Tianjin) is the research and development institution of Sunflower Pharmaceutical Group, mainly engaged in the research and development of ginseng monomer drugs (anticancer drugs, cardiovascular and cerebrovascular drugs, arthritis drugs), ginseng component drugs and ginseng functional foods, as well as the production of refined drugs and private drugs. Possess the key technologies and core intellectual property rights of ginseng processing; Now it has more than 20 core intellectual property rights, obtained many international PCT invention patents from the United States, the European Union, Japan and South Korea, and won many national science and technology awards, including the National Technology Invention Award 10. Enterprises will become national scientific research centers to promote regional industrial upgrading and technological upgrading; Establish a big health industry base, integrate international excellent categories, and set a benchmark for big health industry.